[속보] Celltrion “Anti-drug, 5.4 days until recovery…3 days shorter than placebo 8.8 days”

The Ministry of Food and Drug Safety announced on the 29th that it has initiated a license review for’Rekironaju’, Celltrion’s novel coronavirus infection (Corona 19) antibody treatment. Celltrion applied for permission from the Korean Food and Drug Administration, and at the same time initiated procedures to obtain emergency use approval in the United States and Europe. The photo shows the cure that was released to the media on the 22nd. yunhap news

Celltrion’s COVID-19 antibody treatment,’Rekironaju’, has been confirmed to reduce the incidence of severely ill patients requiring hospitalization in phase 2 clinical trials by 54%.

The time to recover was also shortened by more than 3 days from 8.8 days to 5.4 days, and it was confirmed that the treatment effect was even higher for the elderly over 50 years old.

Celltrion announced the results of phase 2 clinical trials of Rekirona, a COVID-19 treatment, through a public announcement on the 13th. As a result of the phase 2 clinical trial, it was revealed that safety was proven because no specific safety evaluation was found in the treatment group.

Rekironaju reduced the incidence of severely ill patients by 68% in moderately ill patients aged 50 years or older, and shortened the recovery period for moderately ill patients aged 50 or older by 5-6 days or more.

Prior to this, Celltrion applied for conditional use of Rekkirona to the Ministry of Food and Drug Safety. With the completion of phase 2 clinical trials, it will acquire permission to use phase 3 conditionally.

If Celltrion’s treatment is approved by the Ministry of Food and Drug Safety, it will be listed as the first domestic Corona 19 treatment.

Meanwhile, the clinical results were announced at 6 pm on the 13th at the academic conference of the Korean Pharmaceutical Association.